Memo

To: North Carolina Newborn Screening Stakeholders

From: Scott Shone, PhD, HCLD(ABB)
Director, NC State Laboratory of Public Health

Date: July 13, 2021

Re: Newborn Screening Reporting Change for Amino Acids and Acylcarnitines

Today, the North Carolina State Laboratory of Public Health (NCSLPH) Newborn Screening Program will begin reporting the amino acid and acylcarnitine profiles from newborn screening specimens by disorder instead of analyte. This change will result in a difference in the appearance of the newborn screening results report.

Abnormal and borderline amino acid or acylcarnitine profiles will no longer solely list the interpretation and concentration of elevated biomarker(s). Instead, the report will also include the associated disorder acronym and biomarker reference range(s).

The results report will also include instructive comments depending on the result. The comment for borderline amino acid or acylcarnitines is: “Please re-collect and re-submit a Repeat Newborn Screen.” The comment for abnormal amino acid or acylcarnitines is: “Abnormal Results for Amino Acid and Acylcarnitine profiles are reported to the UNC Division of Genetics and Metabolism Follow-Up Clinicians.” Abnormal screening results will also be communicated to the newborn’s health care provider by the UNC Division of Genetics and Metabolism Follow-Up Clinicians. The Follow-up Program will provide consultation services and recommendations for follow-up testing.

For questions about newborn screening laboratory testing, please contact the NCSLPH Newborn Screening Program at 919-807-8938.